PD-1 Blockade in Mismatch Repair Deficient, Locally Advanced Rectal Cancer
Charles Muller, MD
Chair, CGA-IGC Communications Committee
Does PDL-1 blockade therapy allow for non-operative management of MMR deficient locally advanced rectal cancer?
“I’m obviously a big advocate of this approach, but I realize that it’s challenging because it is not yet standard of care” – Andrea Cercek, MD, Memorial Sloan Kettering Cancer Center.
This episode, hosted by Matt Yurgelun, MD from Dana Farber Cancer Center in Boston, MA features Zsofia Stadler, MD & Andrea Cercek, MD, both medical oncologists at Memorial Sloan Kettering Cancer in New York, NY who are